Johnson & Johnson to Expand Cardiovascular Segment with Abiomed Acquisition     Johnson & Johnson has entered into a definitive agreement to acquire Abiomed, developer of breakthrough heart, lung and kidney support technologies, for approximately $16.6 billion. The transaction—expected to be completed prior to the end of the first quarter of 2023—will broaden Johnson & Johnson …

Johnson & Johnson to Expand Cardiovascular Segment with Abiomed Acquisition Read More »